Typesetting | Shuicheng WenApril 2024, GSK（GSK）In a Phase 2 clinical trial, its candidate was confirmed.mRNA Influenza VaccineIn PreventionInfluenza AIn terms of efficacy, it has outperformed the approved inactivated influenza vaccines, but for the "historically challenging problem"BTypeInfluenzaaspect failed to achieve the same effect. The mRNA vaccine, co-developed with GSK,CureVac says it will conduct targeted optimization of the mRNA vaccine to enhance its preventive capabilities.Influenza BThe effect.On September 11, 2024, GSK released new Phase 2 clinical trial data showing that the optimized mRNA COVID-19 vaccine can produce responses in both young and elderly adults comparable to those of conventional flu vaccines.Influenza AAndInfluenza BSignificant immune response。This clinical trial recruited 250 healthy adults aged 18-64 and 250 healthy adults aged 65-85. The results showed that the candidate mRNA vaccine produced an acceptable immune response to both influenza A and influenza B viruses.GSK stated that the interim data also indicated that the various mRNA vaccine formulations tested had acceptable safety and reactogenicity.In July 2024, GSK$430 millionGSK has acquired all rights to CureVac's candidate mRNA flu vaccine and COVID-19 vaccine. GSK stated that it will continueBy investing and collaborating to develop and optimize its mRNA capabilities, including those based on artificial intelligence（AI）The optimization of mRNA sequences, the design and manufacture of nanoparticle delivery carriers.GSK said the latest clinical trial resultsConfirmed that the mRNA platform can generate strong overall antibody titers and has acceptable safety, planning to advance the vaccine into Phase 3 clinical trials.。GSK Chief Scientific OfficerTony WoodDr. said,This clinical trial marks a significant advancement in our mRNA program, and the data supports our progression to the later stages of development. Our ultimate goal is to develop a new best-in-class vaccine that offers greater protection during flu season.In the race to bring the first mRNA flu vaccine to market, GSK's peers have encountered the same issue when it comes to influenza B virus.ModernaIs the only company that has already achieved complete success. In a Phase 3 clinical trial conducted a year ago, Moderna's modified mRNA vaccine candidate was able to induce a higher immune response against the primary strain compared to GSK's approved inactivated influenza vaccine, Fluarix.BType FluAntibody Levels of Virus Strains. While Pfizer andThe candidate mRNA influenza vaccine developed by BioNTech showed efficacy in Phase 3 clinical trials.BThe protective effect against type influenza, but only for people under 65 years old.
SettingsStarmark, so as not to miss exciting tweetsWelcome to share on Moments and WeChat groups.To promote the dissemination and exchange of cutting-edge research, we have established severalProfessional Exchange Group, Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include a note when adding WeChat:School/Professional/Name, ifPI/Professor, please also indicate.
PointIn view, Convey Your Taste
